HOME>Corporate Information>Materiality

Materiality

In accordance with the corporate philosophy of “contributing to the healthier lives of people around the world through the creation of pharmaceuticals,” the Mitsubishi Tanabe Pharma Group believes that its ability to survive and grow depends on the provision of social value and a contribution to the achievement of a sustainable society through the Group’s business activities. To clarify that idea and reinforce our initiatives, we have designated material issues that we need to address as materiality. The Group has positioned these material issues as an important part of its decision-making process, and on that basis, the Group is implementing its business activities.

Process of Designating Material Issues

Step 1: Identify social issues that need to be considered

In designating material issues, the Group considered not only international guidelines and GRI standards but also SASB*1 pharmaceutical industry evaluation standards, ATM index*2 evaluation items, and others. In this way, social issues that need to be considered were identified in a comprehensive manner.

  1. *1 : Sustainability Accounting Standards Board. An NPO based in the U.S. that sets and discloses sustainability evaluation standards by industry.
  2. *2 : Access to Medicine Index. An index that analyzes and ranks 20 of the world's top pharmaceutical companies on how they make medicines more accessible. Implemented by the Access to Medicine Foundation, an NPO based in the Netherlands.
Step 2: Prioritize social issues

For the social issues identified in step 1, their importance for the Group was evaluated with consideration for such factors as the Group’s values and major policies, strategies and specific activity objectives, and risk-related information.
In addition, to evaluate the importance of these issues for stakeholders, we analyzed and organized items that are considered to be important by evaluation institutions that work to promote responsible investing on behalf of external stakeholders. From these two perspectives, we created a materiality map and narrowed down the issues to those with high priority.

figure01
Step 3: Confirm appropriateness and designate material issues

We designated the material issues after the validity of the materiality map was confirmed through consultation with experts from inside and outside the Company.

Material Issues and Major Initiatives

For the seven material issues that were designated through the above process, we organized and confirmed their relevance in regard to major initiatives, the SDGs, the Group’s Code of Conduct, and theMOS indices of KAITEKI upheld by the Mitsubishi Chemical Holdings Corporation (MCHC) Group, of which Mitsubishi Tanabe Pharma is a member.

Material Issues Major Initiatives Related SDGs Code of
Conduct
Related MOS Indices*
① Pharmaceuticals and healthcare services with differentiated value Providing pharmaceuticals 3 GOOD HEALTH AND WELL-BEING 1.Creation of Pharmaceuticals H-1(Contribute to medical treatment)
H-2(Contribute to the prevention and early detection of diseases)
9 INDUSTRY,INNOVATION AND INFRASTRUCTURE
②Reliable products and sustainable supply Building systems for a sustainable supply of reliable pharmaceuticals 3 GOOD HEALTH AND WELL-BEING 2.Safety
3.Quality Assurance
C-1 (Endeavor to earn greater recognition of corporate trust from society)
12 RESPONSIBLE CONSUMPTION AND PRODUCTION
③Appropriate use of products Establishing a drug consultation center, collecting safety information, and providing information related to the appropriate use of products. 3 GOOD HEALTH AND WELL-BEING 5.Product and Medical Information C-1 (Endeavor to earn greater recognition of corporate trust from society)
12 RESPONSIBLE CONSUMPTION AND PRODUCTION
④Ethics, fairness and sincerity in business practices Working to cultivate an awareness of compliance issues, establishing and observing a variety of policies, and establishing hotlines related to compliance and harassment. 12 RESPONSIBLE CONSUMPTION AND PRODUCTION 11. Respect for Human Rights
12.Assurance of Fair Business
C-1 (Endeavor to earn greater recognition of corporate trust from society)
16 PEACE,JUSTICE AND STRONG INSTITUTIONS
⑤Stakeholder engagement Implementing timely, appropriate information disclosure regarding financial information, violations, etc.; providing information related to diseases; implementing dialogue with investors 12 RESPONSIBLE CONSUMPTION AND PRODUCTION 9.Disclosure C-2 (Promote communication and work in concert with stakeholders)
⑥Employee health, diversity and inclusion Taking steps to establish a work environment that enables all employees to participate actively, including promotion of health management; maternity leave, childcare leave, and nursing-care leave; and initiatives for LGBT employees. 3 GOOD HEALTH AND WELL-BEING 7.Our Employees C-2 (Promote communication and work in concert with stakeholders)
5 GENDER EQUALITY
8 DECENT WORK AND ECONOMIC GROWTH
⑦Social contribution activities for health Providing support for patient organizations, research, the provision of vaccines in developing countries, and the GHIT Fund 3 GOOD HEALTH AND WELL-BEING 13.Responsibilities as a Corporate Citizen C-2(Promote communication and work in concert with stakeholders)
9 INDUSTRY,INNOVATION AND INFRASTRUCTURE
17 PARTNERSHIPS FOR THE GOALS

* For further information about MOS Indices, please see the MCHC website.
http://www.mitsubishichem-hd.co.jp/english/sustainability/kpi/